

Ontario Public Drug Programs

Drug Submission Status

Report for November 2017

Complete Streamlined Multiple-Source

Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Accord Healthcare Inc.	ACH-Escitalopram	Ciprallex	escitalopram oxalate	10mg	FC tablet	02434652
Accord Healthcare Inc.	ACH-Escitalopram	Ciprallex	escitalopram oxalate	20mg	FC tablet	02434660
Auro Pharma Inc.	Auro-Nitrofurantoin	Macrobid	nitrofurantoin	100mg	capsule	02466392
CellChem Pharmaceuticals Inc.	CCP-Anastrozole	Arimidex	anastrozole	1mg	FC tablet	02458799
Taro Pharmaceuticals Inc.	Taro-Testosterone Gel	AndroGel	testosterone	1% w/w	topical gel 2.5 g gel/packet	02463792

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Taro Pharmaceuticals Inc.	Taro-Testosterone Gel	AndroGel	testosterone	1% w/w	topical gel 5.0 g gel/packet	02463806
Sanis Health Inc.	Atorvastatin	Lipitor	atorvastatin calcium	10mg	FC tablet	02348705
Sanis Health Inc.	Atorvastatin	Lipitor	atorvastatin calcium	20mg	FC tablet	02348713
Sanis Health Inc.	Atorvastatin	Lipitor	atorvastatin calcium	40mg	FC tablet	02348721
Sanis Health Inc.	Atorvastatin	Lipitor	atorvastatin calcium	80mg	FC tablet	02348748